A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more interesting than another model launch, and a lot less tidy.
The Suzhou-based company says the round includes Oman Investment Authority, alongside returning backers Asia Investment Capital, Granite Asia and Sinovation Ventures, plus new participation from CMB International. That is serious institutional sponsorship. It also follows roughly US$600 million raised across multiple rounds, including a nearly US$300 million Series C. Nobody should confuse a large private funding total with a finished business, but it does give MegaRobo a meaningful runway in a capital-hungry corner of technology.
Money Is Chasing the Physical Feedback Loop
Most of the AI frenzy has lived on screens. Models digest text, images, code and video, then spit out something plausible. Scientific work is a different animal. A hypothesis needs an experiment. An experiment needs equipment, protocols, samples, controls, execution, data handling and somebody—or something—able to interpret what failed. The real value sits in closing that loop repeatedly without turning every iteration into a bespoke consulting project.
MegaRobo calls its platform One Intelligence Stack. The name has a little corporate varnish on it, sure, but the underlying idea is sound: connect models and agents with workflows, software, robotics, scientific instruments and machine-readable feedback. The company is applying that setup first to pharmaceutical research and drug discovery, where the cost of slow or poorly coordinated experimentation is brutal.
That focus matters. Drug R&D does not reward flashy demos for long. Customers want reliable throughput, traceable data and useful decisions. If an AI-designed experiment cannot be executed consistently, the clever algorithm becomes a very fancy PowerPoint slide.
Evidence of Adoption, Not Yet Proof of Dominance
MegaRobo says it has delivered products and technologies to more than 500 customers, including pharmaceutical companies, biotech groups, drug-discovery organizations and research institutions. Its Megalaxy Lab platform has served more than 200 customers. Those are encouraging figures because they suggest this is not a laboratory-only concept hunting for a buyer.
Still, the release does not disclose revenue, recurring revenue, gross margins, customer retention, utilization rates or the terms and valuation of this financing. Those omissions are common in private-company announcements, but they are not small details. Building and operating laboratory automation can be a demanding business: hardware needs support, workflows need validation, and scientific customers rightly move with caution when data quality is on the line.
- Commercial test: Can customer use broaden from individual deployments into standardized, repeatable infrastructure?
- Operational test: Can MegaRobo maintain reliable execution as lab activity expands across regions and use cases?
- Economic test: Does software and workflow value rise fast enough to offset the labor and capital intensity around physical systems?
Those questions are not a knock on the company. They are the bill that comes due for every outfit promising to merge sophisticated software with real-world machinery. The gap between a capable automation vendor and a durable infrastructure platform is wide enough to swallow plenty of funding rounds.
Poreva Open Could Be More Than a Marketing Exercise
The most revealing item here may be Poreva Open, a global AI protein-design challenge launched with partners including Tencent Cloud and Twist Bioscience. MegaRobo says Megalaxy Lab will provide wet-lab validation for more than 10,000 protein design sequences. That is a concrete attempt to make experimental validation available at scale, rather than leaving model developers to compare scores on paper.
Protein design is exactly where the distinction matters. A computational prediction may look terrific until biology gets its say. Real wet-lab results provide a tougher benchmark, and a common benchmark could make MegaRobo more valuable to researchers and AI developers if participation produces credible, structured data. The important word is if. Open challenges generate attention; durable platforms generate repeat usage after the contest banners come down.
AI for science earns its keep only when the physical result is better, faster or more reproducible than the old workflow.
Expansion Needs Discipline Along With Ambition
MegaRobo plans to invest in core technology and expand globally across North America, Europe, the Middle East and Asia. The backing from OIA fits that international direction. Yet global lab infrastructure is not a simple software export. Different customers have different equipment, regulatory expectations, purchasing cycles and data practices. Expansion can create real scale, but it can also chew through cash with remarkable efficiency if local execution gets sloppy.
My read is cautiously positive. MegaRobo is pursuing a genuine bottleneck in AI: getting intelligence out of the chat window and into controlled physical work. Its customer counts, deep investor roster and stated laboratory-validation capacity give the story more substance than the usual AI fog machine. The next proof point is not another grand slogan about the physical world. It is whether the company can show that its stack delivers repeatable scientific outcomes and a business model sturdy enough to carry the machinery behind them.